CR9053A - Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia - Google Patents

Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia

Info

Publication number
CR9053A
CR9053A CR9053A CR9053A CR9053A CR 9053 A CR9053 A CR 9053A CR 9053 A CR9053 A CR 9053A CR 9053 A CR9053 A CR 9053A CR 9053 A CR9053 A CR 9053A
Authority
CR
Costa Rica
Prior art keywords
phenyl
group
epilepsy
alkyl
ethanodiol
Prior art date
Application number
CR9053A
Other languages
English (en)
Inventor
Yong Moon Choi
Robert Gordon
Gerald P Novak
Carlos R Plata-Salaman
Roy E Twyman
H Steve White
Boyu Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR9053A publication Critical patent/CR9053A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion se refiere a metodos para prevenir, tratar, revertir, inhibir o detener la epilepsia y epiletogenesis en un sujeto, que comprende administrar al sujeto en necesidad del mismo una cantidad terapeuticamente efectiva de un compuesto seleccionado del grupo que consiste en la formula (I) y formula (II), o un sal o ester farmaceuticamente aceptable del mismo.
CR9053A 2004-09-16 2007-04-13 Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia CR9053A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61027604P 2004-09-16 2004-09-16
US69862505P 2005-07-12 2005-07-12
US70724205P 2005-08-11 2005-08-11

Publications (1)

Publication Number Publication Date
CR9053A true CR9053A (es) 2009-10-30

Family

ID=36087909

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9053A CR9053A (es) 2004-09-16 2007-04-13 Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia

Country Status (22)

Country Link
US (2) US20060194873A1 (es)
JP (1) JP2008513466A (es)
KR (1) KR20070057939A (es)
CN (1) CN101056629B (es)
AT (1) ATE464044T1 (es)
AU (1) AU2005287174B2 (es)
BR (1) BRPI0515374A (es)
CA (1) CA2580640A1 (es)
CO (1) CO6382111A2 (es)
CR (1) CR9053A (es)
DE (1) DE602005020667D1 (es)
DK (1) DK1809273T3 (es)
EA (1) EA200700642A1 (es)
ES (1) ES2342185T3 (es)
HR (1) HRP20100304T1 (es)
IL (1) IL181910A0 (es)
MX (1) MX2007003278A (es)
NO (1) NO20071921L (es)
NZ (1) NZ553813A (es)
PT (1) PT1809273E (es)
RS (1) RS51269B (es)
WO (1) WO2006033947A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1202720A4 (en) * 1999-08-10 2004-02-25 Uab Research Foundation USE OF GABA AGONISTS FOR THE TREATMENT OF SPASTIC DISEASES, CONVULSIONS AND EPILEPSY
BRPI0516112A (pt) * 2004-10-15 2008-08-26 Janssen Pharmaceutica Nv métodos para neuroproteção
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
US7632963B2 (en) * 2006-10-06 2009-12-15 Janssen Pharmaceutica Nv Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
RU2632659C2 (ru) 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
JP6062077B2 (ja) * 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝
WO2014142547A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same
CN109071424B (zh) * 2016-02-29 2022-01-14 生物药品解决方案有限公司 氨基磺酸酯衍生物化合物、其制备方法及用途
CN106053510A (zh) * 2016-05-16 2016-10-26 山东省分析测试中心 一种基于氢核磁共振快速测定普瑞巴林原料药纯度的方法
KR102421006B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
JP2023536341A (ja) * 2020-08-06 2023-08-24 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む経口用固形製剤及びその製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
AU3304997A (en) * 1996-05-31 1998-01-05 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
JP2002536409A (ja) * 1999-02-09 2002-10-29 ユニバーシティ オブ バージニア パテント ファウンデーション フェルバメートから誘導される化合物
CA2379365C (en) * 1999-07-26 2009-11-17 Sk Corporation Transnasal anticonvulsive compositions and modulated process
DE60223506T2 (de) * 2001-02-27 2008-09-18 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen
DE60220043T2 (de) * 2001-02-27 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder

Also Published As

Publication number Publication date
ATE464044T1 (de) 2010-04-15
EA200700642A1 (ru) 2007-10-26
CO6382111A2 (es) 2012-02-15
AU2005287174B2 (en) 2012-01-12
DK1809273T3 (da) 2010-08-02
US20110152362A1 (en) 2011-06-23
MX2007003278A (es) 2007-10-08
WO2006033947A2 (en) 2006-03-30
CA2580640A1 (en) 2006-03-30
PT1809273E (pt) 2010-05-10
HK1105583A1 (en) 2008-02-22
BRPI0515374A (pt) 2008-07-22
JP2008513466A (ja) 2008-05-01
DE602005020667D1 (de) 2010-05-27
KR20070057939A (ko) 2007-06-07
NZ553813A (en) 2010-09-30
ES2342185T3 (es) 2010-07-02
US20060194873A1 (en) 2006-08-31
CN101056629B (zh) 2012-01-11
RS51269B (sr) 2010-12-31
NO20071921L (no) 2007-06-12
IL181910A0 (en) 2007-07-04
HRP20100304T1 (hr) 2010-09-30
CN101056629A (zh) 2007-10-17
WO2006033947A3 (en) 2006-06-29
AU2005287174A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
CO6382111A2 (es) Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia
ECSP088179A (es) Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
DK1408953T3 (da) Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom
YU68003A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju i lečenju bipolarnih poremećaja
TW200744575A (en) Methods of treating epileptogenesis
IL157594A0 (en) Carbamate compounds for use in preventing or treating anxiety disorders
MX2009004553A (es) Metodos para el tratamiento de trastornos cocleares y vestibulares.
BRPI0520451A2 (pt) métodos para tratamento de distúrbios associados a substáncias quìmicas
TW200701978A (en) Methods of treating epileptogenesis and epilepsy
IL159847A0 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
CY1110672T1 (el) Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)